NIJMEGEN, Netherlands & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aiosyn, a pioneering pathology software company specializing in AI-powered solutions for cancer and kidney disease, and Pramana, an industry ...
In a trial, a model gauging transplant rejection risk using donor-derived cell-free DNA and other parameters safely reduced invasive biopsies. A ‘liquid biopsy’ incorporating donor-derived cell-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback